Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: The role of cabazitaxel in the continuum of care

摘要

Many patients with metastatic, castration-resistant prostate cancer (mCRPC) experience disease progression during or following first-line docetaxel therapy; until recently, second-line treatment approaches have been limited. Within the last 2 yr, novel therapies able to prolong survival in the postdocetaxel setting have emerged, including the novel semisynthetic taxane cabazitaxel. Cabazitaxel has the ability to overcome taxane resistance in vitro and in vivo and has demonstrated activity in docetaxel-sensitive and docetaxel-resistant cell lines and tumor models [1]. In addition, unlike docetaxel and paclitaxel, cabazitaxel has demonstrated the ability to cross the blood-brain barrier and may be effective in patients with cerebral or spinal cord metastases.